Weber A H, Scribner R K, Marks M I
Chemotherapy. 1985;31(6):456-65. doi: 10.1159/000238374.
We tested ciprofloxacin, a new quinoline derivative, against 783 gram-positive and gram-negative bacteria utilizing either standardized microbroth or agar dilution methods. Ciprofloxacin activity was compared to that of cephalosporins, enoxacin, norfloxacin, ampicillin, chloramphenicol, tobramycin, ticarcillin, erythromycin and trimethoprim/sulfamethoxazole. MIC90 values (range) in micrograms/ml were: Pseudomonas aeruginosa = 1 (less than or equal to 0.015-8); Staphylococcus spp. = 0.12 (less than or equal to 0.015-1); Enterobacteriaceae = 0.03 (less than or equal to 0.015-1); Haemophilus influenzae = 0.015 (less than or equal to 0.004-0.03); Streptococcus faecalis = 2 (0.5-4). The MIC90 of ciprofloxacin for 98 tobramycin-resistant isolates was 2.0 micrograms/ml. Ciprofloxacin was stable at temperatures of 35, 22, 4, -20 and -70 degrees C for up to 15 weeks. Varying the inoculum from 10(3) to 10(7) colony forming units per ml or the pH from 6-9 resulted in no increase in the MIC. Of the new quinoline derivatives tested, ciprofloxacin demonstrated consistently superior antibacterial activity. Ciprofloxacin may be particularly effective for oral administration in infections requiring prolonged antibiotic therapy, such as bone, joint, and complicated soft tissue infections, and in pulmonary infections in patients with cystic fibrosis.
我们采用标准微量肉汤或琼脂稀释法，用一种新型喹啉衍生物环丙沙星对783株革兰氏阳性菌和革兰氏阴性菌进行了测试。将环丙沙星的活性与头孢菌素、依诺沙星、诺氟沙星、氨苄西林、氯霉素、妥布霉素、替卡西林、红霉素和甲氧苄啶/磺胺甲恶唑的活性进行了比较。以微克/毫升为单位的MIC90值（范围）如下：铜绿假单胞菌=1（小于或等于0.015 - 8）；葡萄球菌属=0.12（小于或等于0.015 - 1）；肠杆菌科=0.03（小于或等于0.015 - 1）；流感嗜血杆菌=0.015（小于或等于0.004 - 0.03）；粪肠球菌=2（0.5 - 4）。环丙沙星对98株耐妥布霉素菌株的MIC90为2.0微克/毫升。环丙沙星在35、22、4、-20和-70摄氏度下可稳定长达15周。将接种量从每毫升10(3)至10(7)个菌落形成单位或pH值从6 - 9变化，MIC均未增加。在所测试的新型喹啉衍生物中，环丙沙星表现出始终如一的卓越抗菌活性。环丙沙星对于需要长期抗生素治疗的感染，如骨、关节和复杂软组织感染，以及囊性纤维化患者的肺部感染，口服给药可能特别有效。
